pimasertib
Small moleculeexperimental
Clinical trial activity
16 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00982865)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Brain Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Hematologic Neoplasms · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 2
- Mutation · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F- Mol. weight
- 431.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107832 ↗
Also known as
- as703026
- as 703026
- as-703026
- as-703026
- as-703026
- emd 1036239
- emd 1036239
- msc-1236369b
- msc1936369b
- msc1936369b
- msc-1936369b
- msc-1936369b
- n-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
- pimasertib
- pimasertib
- pimasertib
- pimasertib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06208657 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2024 | Australian & New Zealand Childhood Hematology & Oncology Group, Bristol-Myers Squibb, C17 Council, Day One Biopharmaceuticals, Inc., Kazia Therapeutics Limited, Medical Research Future Fund (MRFF), Stand Up To Cancer, University of Toronto |
| NCT07121829 | Phase 1 | May 2, 2022 | Day One Biopharmaceuticals, Inc. |
| NCT04789668 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2021 | University of Texas at Houston |
| NCT01992874 | Phase 1 | Nov 1, 2013 | Merck Serono |
| NCT01985191 | Phase 1 | Nov 1, 2013 | Merck KGaA, Sanofi |
| NCT01936363 | Phase 2 | Sep 1, 2013 | Merck KGaA, Merck Serono, Sanofi |
| NCT01693068 | Phase 2 | Dec 1, 2012 | Merck KGaA, Merck Serono |
| NCT01713036 | Phase 1 | Nov 1, 2012 | Merck KGaA, Merck Serono |
| NCT01668017 | Phase 1 | Sep 1, 2012 | Merck KGaA, Merck Serono |
| NCT01378377 | Phase 1 | Jun 1, 2011 | Merck KGaA, Merck Serono |
| NCT01390818 | Phase 1 | May 1, 2011 | Merck KGaA, Merck Serono, Sanofi |
| NCT01357330 | Phase 1 | May 1, 2011 | Sanofi |
| NCT01085331 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2010 | Merck Serono |
| NCT01016483 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2009 | Merck KGaA, Merck Serono |
| NCT00957580 | Phase 2 | Sep 1, 2009 | Merck KGaA, Merck Serono |
| NCT00982865 | Phase 1 | Dec 1, 2007 | Merck KGaA, Merck Serono |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck Serono | For profit | 11 | 7 | 2 | 2007 |
| Merck KGaA | For profit | 10 | 4 | 2 | 2007 |
| Sanofi | For profit | 4 | 2 | 2 | 2011 |
| Day One Biopharmaceuticals, Inc. | For profit | 2 | 1 | 2 | 2022 |
| Australian & New Zealand Childhood Hematology & Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2024 |
| C17 Council | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Kazia Therapeutics Limited | For profit | 1 | 0 | 1 | 2024 |
| Medical Research Future Fund (MRFF) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2024 |
12 organizations
Page 1 / 1